ITEM VIEW

Risk factors for recurrence of haemoptysis following bronchial artery embolisation for life-threatening haemoptysis

dc.contributor.authorVan Den Heuvel M.M.
dc.contributor.authorEls Z.
dc.contributor.authorKoegelenberg C.F.
dc.contributor.authorNaidu K.M.
dc.contributor.authorBolliger C.T.
dc.contributor.authorDiacon A.H.
dc.date.accessioned2011-05-15T16:16:46Z
dc.date.available2011-05-15T16:16:46Z
dc.date.issued2007
dc.identifier.citationInternational Journal of Tuberculosis and Lung Disease
dc.identifier.citation11
dc.identifier.citation8
dc.identifier.issn10273719
dc.identifier.urihttp://hdl.handle.net/10019.1/13929
dc.description.abstractSETTING: Life-threatening haemoptysis is a frequent and often fatal complication in areas with a high prevalence of tuberculosis (TB). Bronchial artery embolisation remains the standard initial treatment. Subsequent curative measures, such as surgical resection of the focus of haemorrhage, are generally recommended to prevent recurrence, but risk-based selection criteria have not been established. OBJECTIVES: To identify risk factors for the recurrence of haemoptysis following embolisation. DESIGN: Baseline characteristics were obtained from consecutive patients with life-threatening haemoptysis who were successfully embolised and followed up for at least 12 months. RESULTS: Recurrence of haemoptysis was observed in 47% and was associated with increased mortality compared to patients without recurrence (31% vs. 10%, P = 0.021). Patients with recurrence experienced residual mild haemoptysis beyond the first week after embolisation (odds ratio [OR] 7.2), received blood transfusions (OR 5.3) or presented with an aspergilloma (OR 5.1). Conversely, the presence of active TB amenable to treatment (OR 0.3) protected patients from these events. Radiographic or angiographic appearance did not predict recurrence. CONCLUSIONS: Recurrence of haemoptysis following embolisation for life-threatening haemoptysis is common and is associated with high mortality. The results of this study can contribute to the risk assessment of these patients and guide decisions regarding the urgency of definitive therapy. © 2007 The Union.
dc.subjecttuberculostatic agent
dc.subjectadult
dc.subjectangiography
dc.subjectarticle
dc.subjectartificial embolism
dc.subjectaspergillosis
dc.subjectblood transfusion
dc.subjectbronchial artery
dc.subjectbronchiectasis
dc.subjectchronic bronchitis
dc.subjectdisease association
dc.subjectfatality
dc.subjectfemale
dc.subjectfollow up
dc.subjecthemoptysis
dc.subjecthuman
dc.subjectlung tuberculosis
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical decision making
dc.subjectMycobacterium tuberculosis
dc.subjectprevalence
dc.subjectpriority journal
dc.subjectrecurrence risk
dc.subjectretrospective study
dc.subjectrisk assessment
dc.subjectrisk factor
dc.subjectthorax radiography
dc.subjecttreatment outcome
dc.subjecttreatment planning
dc.subjecttuberculosis
dc.titleRisk factors for recurrence of haemoptysis following bronchial artery embolisation for life-threatening haemoptysis
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW